HENDERSON, Nev., Jan. 8, 2025 /PRNewswire/ -- VolitionRx Limited (VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, has issued a Business Review of 2024, outlining its key ...
Cameron Reynolds, President and Group Chief Executive Officer, said: "As we head into 2025, Volition is at a pivotal juncture, ready to revolutionize the diagnosis and monitoring of life-altering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback